XTX Topco Ltd Lowers Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

XTX Topco Ltd reduced its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 43.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,495 shares of the biopharmaceutical company’s stock after selling 5,726 shares during the period. XTX Topco Ltd’s holdings in Ultragenyx Pharmaceutical were worth $308,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. UMB Bank n.a. grew its stake in shares of Ultragenyx Pharmaceutical by 58.1% during the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 352 shares during the last quarter. US Bancorp DE grew its stake in Ultragenyx Pharmaceutical by 5.8% in the first quarter. US Bancorp DE now owns 7,143 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 390 shares in the last quarter. Arizona State Retirement System lifted its holdings in Ultragenyx Pharmaceutical by 2.1% during the second quarter. Arizona State Retirement System now owns 20,744 shares of the biopharmaceutical company’s stock worth $853,000 after buying an additional 434 shares during the period. ProShare Advisors LLC lifted its holdings in Ultragenyx Pharmaceutical by 8.7% during the first quarter. ProShare Advisors LLC now owns 6,074 shares of the biopharmaceutical company’s stock worth $284,000 after buying an additional 486 shares during the period. Finally, Headlands Technologies LLC purchased a new stake in Ultragenyx Pharmaceutical during the first quarter worth $28,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Trading Down 1.4 %

NASDAQ RARE opened at $54.43 on Friday. The stock has a market cap of $4.52 billion, a PE ratio of -6.78 and a beta of 0.56. Ultragenyx Pharmaceutical Inc. has a twelve month low of $31.52 and a twelve month high of $60.37. The stock has a fifty day simple moving average of $53.28 and a 200-day simple moving average of $46.69.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.64) by $0.12. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The firm had revenue of $147.03 million for the quarter, compared to analyst estimates of $123.20 million. During the same quarter in the prior year, the company earned ($2.25) EPS. Ultragenyx Pharmaceutical’s revenue was up 35.7% on a year-over-year basis. Research analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.24 EPS for the current year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total value of $1,117,000.00. Following the sale, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at approximately $124,209,562.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have sold 40,675 shares of company stock valued at $2,149,446. Corporate insiders own 5.80% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on RARE shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Monday, September 16th. Wells Fargo & Company upped their target price on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. The Goldman Sachs Group boosted their price target on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Canaccord Genuity Group reissued a “buy” rating and issued a $111.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, July 23rd. Finally, Robert W. Baird upped their target price on Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the stock an “outperform” rating in a research note on Friday, May 31st. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $87.43.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.